摘要
为评估广州市新生儿乙型肝炎疫苗(HepB)接种纳入计划免疫管理后免疫效果。对1992-2007年出生并接种HepB的新生儿2877人,按1992-2001年和2002-2007年出生新生儿分为计划免疫管理前(Ⅰ组)、计划免疫管理后(Ⅱ组)2组,采血检测乙肝病毒表面抗原(HBsAg)、乙肝病毒表面抗体(抗-HBs)和乙肝病毒核心抗体(抗-HBc)。Ⅱ组HBsAg阳性率为0.48%比Ⅰ组的4.54%阳性率下降了80.65%,在统计学意义上有显著差异。抗-HBc阳性率也由36.07%下降为26.73%,Ⅱ组的抗-HBs阳性率为75.19%,高于I组水平。新生儿乙型肝炎疫苗纳入计划免疫管理后群体免疫效果良好,使用不同种类乙肝疫苗效果没有统计学差异。重组(酵母)乙型肝炎疫苗有较好的近期保护效果和免疫原性,与以前使用血源乙型肝炎疫苗效果相当。
To assess the immune efficiency of Hepatitis B（Hep B） vaccine in newborns after introducing Hep B vaccine into the EPI management.2877 newborns immunized with Hep B vaccine born in 1992-2007 were divided into two groups.The subjects born in 1992-2001 before EPI management were merged into group I,the subjects born in 2002-2007 after EPI management were merged into group Ⅱ.Blood samples were collected for detecting HBsAg,anti-HBs and anti-HBs.The results showed that HBsAg positive rate of group Ⅱ and group I is 0.48% and 4.54% respectively.The difference between two groups is of the statistical significance.The anti-HBs positive rate of group Ⅱ is 75.19% which is higher than that of group I.The immune efficiency of HepB in neonatal population after introducing HepB vaccine into EPI management is better than before EPI management.There are not statistical differences between the effect of different HepB vaccine types.The immunogenicity and short-term protective effect of recombinant yeast hepatitis B vaccine is excellent and can compare with the traditional blood-derived hepatitis B vaccine.
出处
《微生物学免疫学进展》
2010年第1期46-49,共4页
Progress In Microbiology and Immunology
